Transmedics Group Inc [TMDX] stock is trading at $66.50, up 6.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TMDX shares have gain 4.07% over the last week, with a monthly amount drifted -21.89%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
Transmedics Group Inc [TMDX] stock has fluctuated between $58.27 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $116.33 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $66.50 at the most recent close of the market. An investor can expect a potential return of 74.93% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 401.09M for the trailing twelve months, which represents a growth of 63.72%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.97 points at the first support level, and at 61.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.97, and for the 2nd resistance point, it is at 71.44.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 8.20. As well, the Quick Ratio is 7.33, while the Cash Ratio is 5.5. Considering the valuation of this stock, the price to sales ratio is 5.56, the price to book ratio is 10.63 and price to earnings (TTM) ratio is 71.24.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Dec 02 ’24 when 1084.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Nov 11 ’24 to sell 1458.0 shares. Meanwhile, Director Basile Edward M sold 6750.0 shares on Nov 05 ’24.
